Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K5 | Q99683 | 3/20 | 0.46 |
| ▸ | BRAF | P15056 | 7/20 | 0.40 |
| ▸ | LCK | P06239 | 3/20 | 0.39 |
| ▸ | KDR | P35968 | 2/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.39 |
| ▸ | SRC | P12931 | 2/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.39 |
| ▸ | YES1 | P07947 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 2/20 | 0.38 |
| ▸ | JAK3 | P52333 | 2/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | WEE1 | P30291 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23839099 | 0.89 | MAP3K5 (0.48) | MAP3K5BRAFLCKKDRMAPK14 | |
| SCHEMBL23839135 | 0.87 | MAP3K5 (0.59) | MAP3K5BRAFLCKKDRMAPK14 | |
| SCHEMBL23839127 | 0.87 | JAK3 (0.53) | MAP3K5BRAFLCKKDRMAPK14 | |
| SCHEMBL23839103 | 0.85 | MAP3K5 (0.51) | MAP3K5BRAFLCKKDRMAPK14 | |
| SCHEMBL23839105 | 0.84 | CCNT1 (0.51) | MAP3K5BRAFLCKFGFR4ABL1 | |
| SCHEMBL23839143 | 0.83 | MAP3K5 (0.47) | MAP3K5BRAFLCKKDRMAPK14 | |
| SCHEMBL23839106 | 0.83 | FGFR4 (0.55) | MAP3K5FGFR4EGFR | |
| SCHEMBL23839144 | 0.82 | MAP3K5 (0.50) | MAP3K5LCKKDRMAPK14FGFR4 | |
| SCHEMBL23839142 | 0.82 | MAP3K5 (0.48) | MAP3K5BRAFLCKKDRMAPK14 | |
| SCHEMBL23839121 | 0.82 | MAP3K5 (0.49) | MAP3K5BRAFLCKKDRMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017484-A1 | INHIBITOR OF BRUTON TYROSINE KINASE | BEIJING RECIPROCAPHARMACEUTICALS CO., LTD. (CN) | 2022-01-20 | — | — | US | disclosed |
| EP-3882241-A1 | INHIBITOR OF BRUTON'S TYROSINE KINASE | Beijing Reciprocapharmaceuticals Co., Ltd. (CN) | 2021-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017484-A1 | INHIBITOR OF BRUTON TYROSINE KINASE | BTK, LYN, SYK | MAP3K5 144/4885BRAF 66/4885LCK 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.